Interplay Between Innate Immunity and the Viral Oncoproteins Tax and HBZ in the Pathogenesis and Therapeutic Response of HTLV-1 Associated Adult T Cell Leukemia

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 8

PMID 35935975

Authors

Hiba El Hajj

Ali Bazarbachi

Affiliations

Soon will be listed here.

Abstract

The Human T-cell Leukemia virus type 1 (HTLV-1) causes an array of pathologies, the most aggressive of which is adult T-cell leukemia (ATL), a fatal blood malignancy with dismal prognosis. The progression of these diseases is partly ascribed to the failure of the immune system in controlling the spread of virally infected cells. HTLV-1 infected subjects, whether asymptomatic carriers or symptomatic patients are prone to opportunistic infections. An increasing body of literature emphasizes the interplay between HTLV-1, its associated pathologies, and the pivotal role of the host innate and adoptive immune system, in shaping the progression of HTLV-1 associated diseases and their response to therapy. In this review, we will describe the modalities adopted by the malignant ATL cells to subvert the host innate immune response with emphasis on the role of the two viral oncoproteins Tax and HBZ in this process. We will also provide a comprehensive overview on the function of innate immunity in the therapeutic response to chemotherapy, anti-viral or targeted therapies in the pre-clinical and clinical settings.

Citing Articles

Viral Oncogenesis: Synergistic Role of Genome Integration and Persistence.

La Frazia S, Pauciullo S, Zulian V, Garbuglia A Viruses. 2025; 16(12.

PMID: 39772271 PMC: 11728759. DOI: 10.3390/v16121965.

Evaluation of ALKBH2 and ALKBH3 gene regulation in patients with adult T-cell leukemia/lymphoma.

Wada Y, Naito T, Fukushima T, Saito M Virol J. 2024; 21(1):316.

PMID: 39633427 PMC: 11619432. DOI: 10.1186/s12985-024-02590-w.

Novel approaches for HTLV-1 therapy: innovative applications of CRISPR-Cas9.

Domingues W, Folgosi V, Sanabani S, Leite Junior P, Assone T, Casseb J Rev Inst Med Trop Sao Paulo. 2024; 66:e48.

PMID: 39194140 PMC: 11348795. DOI: 10.1590/S1678-9946202466048.

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells cereblon through downregulation of target proteins and their downstream effectors.

Wang Y, Shimosaki S, Ikebe E, Iha H, Yamamoto J, Fife N Front Oncol. 2024; 13:1272528.

PMID: 38344143 PMC: 10853999. DOI: 10.3389/fonc.2023.1272528.

Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.

Watanabe T, Yamamoto Y, Kurahashi Y, Kawasoe K, Kidoguchi K, Ureshino H Blood Adv. 2024; 8(6):1345-1358.

PMID: 38190613 PMC: 10945144. DOI: 10.1182/bloodadvances.2023011131.

References

Bazarbachi A, El-Sabban M, Nasr R, Quignon F, Awaraji C, Kersual J . Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1998; 93(1):278-83. View

Raval G, Bidoia C, Forlani G, Tosi G, Gessain A, Accolla R . Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL. Retrovirology. 2015; 12:59. PMC: 4491271. DOI: 10.1186/s12977-015-0186-0. View

Hilburn S, Rowan A, Demontis M, MacNamara A, Asquith B, Bangham C . In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome. J Infect Dis. 2011; 203(4):529-36. PMC: 3071236. DOI: 10.1093/infdis/jiq078. View

Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y . Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010; 116(8):1369-76. DOI: 10.1182/blood-2009-10-247510. View

de La-Roque D, Santos E, Rodrigues E, Mendes da Costa P, Brauer V, Almeida F . The Expression of Tax and HBZ Genes in Serum-Derived Extracellular Vesicles From HTLV-1 Carriers Correlates to Proviral Load and Inflammatory Markers. Front Microbiol. 2022; 13:881634. PMC: 9108699. DOI: 10.3389/fmicb.2022.881634. View

Masaki A, Ishida T, Suzuki S, Ito A, Mori F, Sato F . Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse model. J Immunol. 2013; 191(1):135-44. DOI: 10.4049/jimmunol.1202692. View

Shimoyama M . Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991; 79(3):428-37. DOI: 10.1111/j.1365-2141.1991.tb08051.x. View

Bazarbachi A, Cwynarski K, Boumendil A, Finel H, Fields P, Raj K . Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant. 2014; 49(10):1266-8. DOI: 10.1038/bmt.2014.143. View

Matsuoka M, Yasunaga J . Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. Curr Opin Virol. 2013; 3(6):684-91. DOI: 10.1016/j.coviro.2013.08.010. View

10.

Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y . Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. J Clin Oncol. 2016; 34(34):4086-4093. DOI: 10.1200/JCO.2016.67.7732. View

11.

Philpott S, Buehring G . Defective DNA repair in cells with human T-cell leukemia/bovine leukemia viruses: role of tax gene. J Natl Cancer Inst. 1999; 91(11):933-42. DOI: 10.1093/jnci/91.11.933. View

12.

Kchour G, Rezaee R, Farid R, Ghantous A, Rafatpanah H, Tarhini M . The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology. 2013; 10:91. PMC: 3751834. DOI: 10.1186/1742-4690-10-91. View

13.

Kannagi M . [Immunological aspects of human retrovirus infection]. Nihon Rinsho. 2005; 63 Suppl 4:508-16. View

14.

Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y . VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007; 25(34):5458-64. DOI: 10.1200/JCO.2007.11.9958. View

15.

Kchour G, Tarhini M, Kooshyar M, El Hajj H, Wattel E, Mahmoudi M . Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009; 113(26):6528-32. DOI: 10.1182/blood-2009-03-211821. View

16.

Giam C, Semmes O . HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ. Viruses. 2016; 8(6). PMC: 4926181. DOI: 10.3390/v8060161. View

17.

Portis T, Grossman W, Harding J, Hess J, Ratner L . Analysis of p53 inactivation in a human T-cell leukemia virus type 1 Tax transgenic mouse model. J Virol. 2001; 75(5):2185-93. PMC: 114802. DOI: 10.1128/JVI.75.5.2185-2193.2001. View

18.

Yasuma K, Yasunaga J, Takemoto K, Sugata K, Mitobe Y, Takenouchi N . HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT). PLoS Pathog. 2016; 12(1):e1005372. PMC: 4703212. DOI: 10.1371/journal.ppat.1005372. View

19.

Sze A, Belgnaoui S, Olagnier D, Lin R, Hiscott J, van Grevenynghe J . Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe. 2013; 14(4):422-34. DOI: 10.1016/j.chom.2013.09.009. View

20.

Malpica L, Pimentel A, Reis I, Gotuzzo E, Lekakis L, Komanduri K . Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018; 2(6):607-620. PMC: 5873228. DOI: 10.1182/bloodadvances.2017011106. View